2023年5月12日

分享深生物,醫學人工智能數字病理的先驅和癌症診斷軟件的支持,宣布羅坍來自約翰霍普金斯醫學博士展示了他們的合作研究,利用深在講台上優於算法對前列腺癌診斷支持會話在美國泌尿協會(AUA) 2023年年會。這個聯合研究相比人類病理學家和分級前列腺活檢標本的人工智能算法預測根治性前列腺切除術後生化複發。格裏森評分的一個關鍵元素是前列腺癌和年級可以導致不同的臨床決策。例如,盡管3 + 4和4 + 3格裏森評分是相同的格裏森評分7年代,每個人都有不同的預後。格裏森3 + 4需要積極監測多但往往表現更好的預後比格裏森4 + 3。研究重新評估的診斷284例初步診斷為格裏森年級組2(格裏森評分3 + 4)和約翰霍普金斯醫學行根治性前列腺切除術後從2000年到2014年。這個群體是最具挑戰性的一個組診斷以來許多情況下診斷3 + 4之前可以下調3 + 3或升級到4 + 3。約翰霍普金斯醫學也有14年的隨訪數據患者(平均4年的隨訪),大約16%的患者經曆了前列腺癌複發。ISUP準則改變了在這些時期,所有這些活檢被兩個專家打分,泌尿生殖器的病理學家和第三個專家泌尿生殖器的病理學家擔任不符讀取的搶七。人類病理學家和人工智能算法比較,深生物基於AI的前列腺癌診斷支持軟件DeepDx®前列腺分析所有活檢提供格裏森評分。 The results showed poor agreements between the two pathologists, generating a kappa of 0.17 while grading between the consensus pathology read and the AI algorithm generated a slightly higher kappa of 0.33. Importantly, however, the study suggested that the algorithm can act as a tool that stratifies patients for subsequent biochemical recurrence after radical prostatectomy. This risk stratification has the potential to prevent a lot of unnecessary surgeries and aid in choosing between treatment modalities. Related Posts “It is a meaningful milestone for Deep Bio to conduct a joint research with Johns Hopkins Medicine, one of the top global universities, and the findings are remarkable for prostate cancer diagnosis using AI,” said Sun-Woo Kim , CEO of Deep Bio. “As precise diagnosis and personalization have become the crucial factors in deciding medical decisions for medical professionals, we will focus on bringing innovative deep learning technologies that can unlock new insights in cancer diagnosis and treatment” added he. Deep Bio continues to focus on not only AI diagnostics but also R&D and presenting the results in various international conferences and events. The company also continues to build its presence in the global market through collaboration with overseas digital pathology solution providers in the US, Europe, and India.